Estimation of efficacy of Reduced form of Coenzyme Q10 to seasonal allergy.

Estimation of efficacy of Reduced form of Coenzyme Q10 to seasonal allergy. - Efficacy of Reduced form of CoQ10 to seasonal allergy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020309

Enrollment

Registered

2015-12-24

Start date

2015-12-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Reduced form of CoQ10, 100mg, 4 months Reduced form of CoQ10, 150mg, 4 months placebo, 4 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. age: over 20 y.o. under 65 y.o 2. sex: male and female 3. hospitalization or exogenous: exogenous 4. Possible to take test sample during test periods. 5. If under dietetics or kinesitherapy, continue it during test periods. 6. Have a subjective symptom such as cough, runny nose and sneeze in the period of seasonal allergy over 2 years.

Exclusion criteria

Exclusion criteria: 1. Patients of seasonal allergy. 2. Using medicines such as anti-allergy and steroid. 3. Using Warfarin. 4. Have to use anti-allergy medicine during test periods. 5. Patients of nasal diseases such as nasal catarrh etc. 6. Doctor did not allowed to enrty to this study. 7. Patient of serious desease such as diabetes, liver disease, renal disease, heart disease, immunodeficiency, cancer, anemia, and asthma. Lactating, pregnant and wish to pregnant in this study periods. Use CoQ10 supplement. Entry another clinical study which ongoing or performed within 1 month.

Design outcomes

Primary

Measure	Time frame
Quality of life after 4 months intake.	—

Countries

Japan

Contacts

Public ContactSatoshi Sakurai

imeQ Co. Ltd. Pharmaceutical Division

s-sakurai@imeq.co.jp03-6205-6222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026